 AIM ImmunoTech Inc NYSE:AIM posted second-quarter financial results that showed ample cash on hand, giving the company scope to achieve multiple clinical and regulatory milestones. The Florida-based companys lead candidate Ampligen rintatolimod, an immuno-modulator with broad spectrum activity, is being developed to treat multiple types of cancers, immune disorders, and viral disorders, including coronavirus COVID-19. 